Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS files an F-3 to register up to 75,000 ordinary shares for resale by a selling shareholder. These shares are issuable upon exercise of a warrant (the "Second Amendment warrant shares") with an exercise price of $5.1829 per share and an exercise period ending at 5:00 p.m., Eastern time, on January 23, 2036.
We will not receive proceeds from resale by the selling shareholder; however, we may receive up to $388,717.50 if the holder exercises all Second Amendment warrant shares, and any such proceeds will be used for working capital and general corporate purposes. As context, share capital registered was 89,321,220 ordinary shares as of December 31, 2025.
SOPHiA GENETICS has filed its annual Form 20-F for the year ended December 31, 2025, presenting IFRS-based consolidated financial statements and extensive risk disclosures. The company had 68,486,338 ordinary shares outstanding as of year-end.
The report describes the SOPHiA DDM Platform, a cloud-based multimodal data analytics solution used across oncology, rare and infectious diseases, cardiology, neurology and other areas. Management highlights numerous forward-looking statements and cautions that actual results may differ materially due to detailed risk factors.
Key risks include challenges expanding platform features and data modalities, dependence on sales and marketing execution and strategic relationships, uncertain reimbursement and market adoption, intense competition, ongoing net losses with no assurance of future profitability, heavy reliance on third parties and key personnel, cybersecurity and data privacy threats, and significant regulatory and IVD approval requirements in the U.S. and Europe.
SOPHiA GENETICS reported strong 2025 revenue growth but remains loss-making. Fourth-quarter revenue reached $21.7 million, up 22% year over year, while full-year revenue rose 19% to $77.3 million. Reported gross margin was 67.4% for 2025, with adjusted gross margin at 74.2%.
The company recorded a 2025 IFRS net loss of $79.0 million and an adjusted EBITDA loss of $41.5 million, both larger than in 2024, though year-over-year adjusted EBITDA deterioration was limited to 3%. Management processed more than 391,000 analyses in 2025 and grew core genomics customers to 528.
For 2026, SOPHiA GENETICS guides to revenue between $92 million and $94 million, implying roughly 20–22% growth, and expects an adjusted EBITDA loss between $29 million and $32 million. The company raised $15.5 million via its at-the-market equity program and expanded its credit facility by $25 million, and targets approaching adjusted EBITDA breakeven by the end of 2026 with a move to positive adjusted EBITDA in the second half of 2027.
Zhenyu Xu submitted a Rule 144 notice reporting proposed sales of Common stock. The filing lists recent 10b5-1 sales by Zhenyu Xu, including sales of 4,000 shares on 02/13/2026 and 4,000 shares on 01/13/2026. The broker shown is Morgan Stanley Smith Barney LLC. The "Securities To Be Sold" section lists 608 Restricted Stock Units (dated 02/18/2026) and 4,000 Founders Shares (dated 06/20/2012).
SOPH submitted a Rule 144 notice for the proposed sale of 684 restricted stock units by the issuer, dated 02/18/2026. The filing also lists prior 10b5-1 sales by Daan Guido Maria Van Well on 12/19/2025, 01/05/2026, 01/06/2026, and 01/20/2026, each showing quantities of 2051, 2056, or 684 shares in the excerpt.
Sophic Biosciences reports a proposed sale of restricted stock units by an affiliate. The filing lists 760 restricted stock units proposed for sale on 02/18/2026. The notice also records prior 10b5-1 sales by the same affiliate, including 4,200 shares on 01/06/2026 and 2,021 shares on 01/05/2026.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 reporting proposed dispositions of Common shares and listing recent 10b5-1 sales executed by Philippe Menu.
The excerpt shows multiple 10b5-1 sales: 5,000 shares on 02/12/2026, 608 on 01/20/2026, 5,000 on 01/12/2026, 5,006 on 01/06/2026, and 608 on 12/19/2025.
SOPH affiliate reported proposed and recent insider sales of common stock and restricted stock units. The notice lists a proposed sale of 380 restricted stock units dated 02/18/2026. It also records prior 10b5-1 sales: 381, 2,085, 636, and 380 shares on the dates shown in the filing.
Balderton Capital VI, S.L.P. has updated its ownership disclosure for Sophia Genetics SA, reporting beneficial ownership of 3,301,240 Ordinary Shares of CHF 0.05 per share. These shares are held of record by BCVI, with BCVI Sarl as managing general partner.
The stake represents 4.9% of the outstanding Ordinary Shares, based on 67,579,560 shares outstanding as of June 30, 2025, as reported in a prospectus on Form 424(b)(5). Balderton reports shared voting and dispositive power over all 3,301,240 shares and no sole voting or dispositive power, and each reporting person disclaims beneficial ownership beyond its pecuniary interest.
SOPHiA GENETICS amended its existing credit agreement with Perceptive Credit Holdings to add $25 million of new term loan commitments. This includes a $12.5 million Tranche C that may be drawn subject to customary conditions and a $12.5 million Tranche D that becomes available once trailing twelve‑month revenue exceeds $85 million. Any Tranche C and Tranche D borrowings will mirror existing term loan terms, bear interest at Term SOFR plus 6.25% per year, and mature in 2029.
In connection with the amendment, the company amended and restated a warrant certificate to grant Perceptive rights to purchase up to 275,000 ordinary shares: 75,000 shares exercisable immediately, 100,000 more upon drawing Tranche C, and another 100,000 upon drawing Tranche D. The warrants are exercisable in cash at the holder’s option for up to ten years from each availability date and include customary anti‑dilution adjustments. The company must file resale registration statements for the warrant shares within 30 business days of each availability date and keep them effective until the shares are sold, freely tradable, no longer outstanding, or no longer held by parties with registration rights.